Heron Therapeutics, Inc. (HRTX) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 11, 2026, reports the issuance of a press release containing financial results for the three months ended March 31, 2026. The registrant, Heron Therapeutics, Inc., is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol HRTX.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced "Earnings Press Release" (Exhibit 99.1), which is furnished but not included in the text of this 8-K summary.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It serves solely as a notification that the Q1 2026 results have been announced.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q1 2026 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the company provided updated full-year 2026 financial guidance in the press release.